Friday
June 13, 2025
7:00 AM ET
Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress
Thursday
June 5, 2025
8:28 AM ET
Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting
Saturday
May 31, 2025
8:00 AM ET
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Thursday
May 1, 2025
7:00 AM ET
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
Monday
April 28, 2025
7:00 AM ET
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Tuesday
February 11, 2025
7:00 AM ET
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Monday
February 3, 2025
7:00 AM ET
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025